Novartis, a global pharmaceutical company, has announced a $23 billion investment over five years to expand its manufacturing and research presence across the United States. The company aims to ensure all key Novartis medicines for US patients are produced domestically.
Novartis has officially opened a €40 million ($41.2 million) viral vector manufacturing facility in Mengeš, Slovenia, as part of its broader strategy to enhance cell and gene therapy capabilities across Europe. The site, named VIFA One, represents the company’s first
Novartis has announced a significant expansion of its biopharmaceutical manufacturing site in Singapore. The company is investing US$256 million to enhance its manufacturing productivity, improve operational efficiency, and upskill its workforce. The expansion is a strategic move to address the ‘soaring
Novartis is investing approximately €500 million in its Austrian facilities, building two new cell culture plants at their long-established sites in Kundl and Schaftenau in Tyrol, Austria. They will invest €250 million in the Kundl facility, which is expected to
Rathish Ravindrakumar explains the services the CDMO offers and the importance of sustainability to the pharma supply chain.
Mark Burfoot, VP Research Procurement at Novartis explains how advances in Machine Learning allow procurement to have a more strategic role in optimising life science research.
Stay ahead of trends and best practices 
Exclusive downloads and podcasts 
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
